List of Bio-Path Holdings patents | 6 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10927379 Combination therapy with liposomal antisense oligonucleotides	Patent 10927379 was granted and assigned to Bio-Path Holdings on February, 2021 by the United States Patent and Trademark Office.	Bio-Path Holdings	Bio-Path Holdings	United States Patent and Trademark Office	10927379	February 23, 2021
‌ US Patent 10335428 P-ethoxy nucleic acids for liposomal formulation	Patent 10335428 was granted and assigned to Bio-Path Holdings on July, 2019 by the United States Patent and Trademark Office.	Bio-Path Holdings	Bio-Path Holdings	United States Patent and Trademark Office	10335428	July 2, 2019
‌ US Patent 9744187 p-Ethoxy nucleic acids for liposomal formulation	Patent 9744187 was granted and assigned to Bio-Path Holdings on August, 2017 by the United States Patent and Trademark Office.	Bio-Path Holdings	Bio-Path Holdings	United States Patent and Trademark Office	9744187	August 29, 2017
‌ US Patent 10898506 P-ethoxy nucleic acids for liposomal formulation	Patent 10898506 was granted and assigned to Bio-Path Holdings on January, 2021 by the United States Patent and Trademark Office.	Bio-Path Holdings	Bio-Path Holdings	United States Patent and Trademark Office	10898506	January 26, 2021
‌ US Patent 11041153 P-ethoxy nucleic acids for STAT3 inhibition	Patent 11041153 was granted and assigned to Bio-Path Holdings on June, 2021 by the United States Patent and Trademark Office.	Bio-Path Holdings	Bio-Path Holdings	United States Patent and Trademark Office	11041153	June 22, 2021
‌ US Patent 12012601 Combination therapy with liposomal antisense oligonucleotides	Patent 12012601 was granted and assigned to Bio-Path Holdings on June, 2024 by the United States Patent and Trademark Office.	Bio-Path Holdings	Bio-Path Holdings	United States Patent and Trademark Office	12012601	June 18, 2024